Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)‘s stock had its “outperform” rating reissued by equities researchers at Credit Suisse Group in a research report issued on Tuesday. They currently have a $201.00 price target on the biopharmaceutical company’s stock. Credit Suisse Group’s target price would indicate a potential upside of 252.35% from the company’s previous close.

Several other equities research analysts also recently weighed in on the stock. Jefferies Group LLC restated a “buy” rating and issued a $135.00 target price (down from $275.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday. Needham & Company LLC restated a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Tuesday. Royal Bank Of Canada raised their target price on shares of Intercept Pharmaceuticals from $200.00 to $244.00 and gave the company an “outperform” rating in a research note on Tuesday. Robert W. Baird restated an “outperform” rating and issued a $332.00 target price on shares of Intercept Pharmaceuticals in a research note on Saturday, September 23rd. Finally, Leerink Swann lowered their target price on shares of Intercept Pharmaceuticals from $120.00 to $66.00 and set a “market perform” rating for the company in a research note on Saturday, September 23rd. Three research analysts have rated the stock with a sell rating, eight have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Intercept Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $162.88.

Intercept Pharmaceuticals (ICPT) traded up 2.16% during mid-day trading on Tuesday, reaching $58.24. The company’s stock had a trading volume of 614,402 shares. Intercept Pharmaceuticals has a one year low of $56.49 and a one year high of $172.75. The stock’s market cap is $1.46 billion. The firm’s 50 day moving average is $106.75 and its 200-day moving average is $115.74.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. The company had revenue of $30.89 million during the quarter, compared to the consensus estimate of $27.50 million. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. Intercept Pharmaceuticals’s revenue was up 459.6% compared to the same quarter last year. During the same period last year, the firm earned ($3.14) earnings per share. Equities analysts expect that Intercept Pharmaceuticals will post ($13.99) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/09/28/intercept-pharmaceuticals-inc-icpt-stock-rating-reaffirmed-by-credit-suisse-group.html.

In other Intercept Pharmaceuticals news, Director Daniel G. Welch sold 217 shares of Intercept Pharmaceuticals stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $126.76, for a total value of $27,506.92. Following the completion of the transaction, the director now owns 3,710 shares of the company’s stock, valued at $470,279.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Lisa Bright sold 253 shares of Intercept Pharmaceuticals stock in a transaction on Friday, August 25th. The shares were sold at an average price of $111.31, for a total transaction of $28,161.43. Following the completion of the transaction, the insider now directly owns 23,324 shares of the company’s stock, valued at approximately $2,596,194.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 8,013 shares of company stock valued at $966,747. 9.20% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. WFG Advisors LP increased its holdings in Intercept Pharmaceuticals by 16.4% in the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 125 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 132 shares in the last quarter. US Bancorp DE purchased a new position in Intercept Pharmaceuticals in the first quarter valued at $130,000. IFP Advisors Inc increased its holdings in Intercept Pharmaceuticals by 128.1% in the second quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 730 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new position in Intercept Pharmaceuticals in the first quarter valued at $170,000. 82.19% of the stock is owned by institutional investors.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.